Shreedevi Pandya
Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Muscular Dystrophy, Duchenne | 11 | 2001 | 7 |
Why?
|
Muscular Dystrophies | 23 | 1981 | 28 |
Why?
|
Prednisone | 12 | 1981 | 80 |
Why?
|
Dermatomyositis | 1 | 2011 | 16 |
Why?
|
Glucocorticoids | 2 | 2009 | 107 |
Why?
|
Genetic Vectors | 3 | 1999 | 139 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 78 |
Why?
|
Gene Therapy | 3 | 1999 | 89 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2011 | 67 |
Why?
|
Muscular Dystrophy, Facioscapulohumeral | 2 | 2001 | 8 |
Why?
|
Immunoglobulin G | 1 | 2011 | 191 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 131 |
Why?
|
Severity of Illness Index | 5 | 1996 | 358 |
Why?
|
Adolescent | 28 | 1981 | 891 |
Why?
|
Myositis, Inclusion Body | 2 | 2008 | 7 |
Why?
|
Lentivirus | 2 | 1999 | 20 |
Why?
|
Simian immunodeficiency virus | 2 | 1999 | 12 |
Why?
|
Myotonic Dystrophy | 4 | 1989 | 21 |
Why?
|
Humans | 52 | 1981 | 1856 |
Why?
|
Child | 25 | 1983 | 749 |
Why?
|
Mutation | 1 | 2008 | 340 |
Why?
|
Young Adult | 5 | 2008 | 380 |
Why?
|
Male | 39 | 1981 | 1553 |
Why?
|
Voice | 1 | 2011 | 6 |
Why?
|
Gene Products, rev | 1 | 2001 | 4 |
Why?
|
Telephone | 1 | 2011 | 28 |
Why?
|
Spumavirus | 1 | 2001 | 2 |
Why?
|
Medical Records | 1 | 2011 | 104 |
Why?
|
Gene Deletion | 3 | 1996 | 121 |
Why?
|
HIV-1 | 3 | 1999 | 93 |
Why?
|
Muscle Strength | 2 | 2007 | 21 |
Why?
|
Double-Blind Method | 14 | 1984 | 274 |
Why?
|
Quality of Life | 3 | 2009 | 188 |
Why?
|
Dose-Response Relationship, Drug | 4 | 1991 | 431 |
Why?
|
Adult | 24 | 1984 | 1317 |
Why?
|
Pregnenediones | 2 | 2005 | 3 |
Why?
|
Membrane Glycoproteins | 1 | 2001 | 154 |
Why?
|
Genotype | 3 | 1996 | 175 |
Why?
|
Treatment Outcome | 7 | 1997 | 661 |
Why?
|
Muscles | 13 | 1981 | 111 |
Why?
|
Child, Preschool | 20 | 1983 | 554 |
Why?
|
Middle Aged | 16 | 1989 | 1161 |
Why?
|
Pilot Projects | 5 | 1997 | 264 |
Why?
|
Drug Administration Schedule | 4 | 1991 | 191 |
Why?
|
Female | 21 | 1991 | 1643 |
Why?
|
Isometric Contraction | 3 | 1994 | 22 |
Why?
|
Physical Therapy Modalities | 3 | 1985 | 18 |
Why?
|
Myotonia | 2 | 2007 | 12 |
Why?
|
Muscle, Skeletal | 3 | 2006 | 114 |
Why?
|
Shoulder | 3 | 1994 | 15 |
Why?
|
Cohort Studies | 4 | 2008 | 332 |
Why?
|
Face | 2 | 1997 | 25 |
Why?
|
Neurologic Examination | 1 | 2011 | 64 |
Why?
|
DNA Mutational Analysis | 2 | 2006 | 110 |
Why?
|
Treatment Failure | 1 | 2011 | 88 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 89 |
Why?
|
Muscle Contraction | 3 | 1983 | 77 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 16 |
Why?
|
Caregivers | 1 | 2011 | 50 |
Why?
|
Biopsy | 2 | 2006 | 207 |
Why?
|
Point Mutation | 2 | 1996 | 122 |
Why?
|
Albuterol | 2 | 1998 | 15 |
Why?
|
Anti-Inflammatory Agents | 1 | 2011 | 80 |
Why?
|
Adrenergic beta-Agonists | 2 | 1998 | 39 |
Why?
|
Hand Strength | 2 | 2001 | 18 |
Why?
|
Population Surveillance | 2 | 2006 | 70 |
Why?
|
Spinal Muscular Atrophies of Childhood | 1 | 2009 | 6 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2010 | 64 |
Why?
|
Palliative Care | 1 | 2011 | 65 |
Why?
|
Adrenal Cortex Hormones | 1 | 2010 | 76 |
Why?
|
Gene Duplication | 1 | 2008 | 7 |
Why?
|
Dystrophin | 1 | 2008 | 7 |
Why?
|
Gene Frequency | 1 | 2008 | 42 |
Why?
|
Genetic Markers | 1 | 2008 | 78 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2011 | 145 |
Why?
|
Genetic Testing | 1 | 2008 | 49 |
Why?
|
Patient Care Team | 1 | 2009 | 119 |
Why?
|
Drug Eruptions | 1 | 2008 | 26 |
Why?
|
Joints | 2 | 1981 | 19 |
Why?
|
Clinical Protocols | 2 | 1994 | 93 |
Why?
|
Disability Evaluation | 1 | 2008 | 61 |
Why?
|
Recombinant Proteins | 1 | 2010 | 290 |
Why?
|
Software | 2 | 1987 | 92 |
Why?
|
Nifedipine | 1 | 1987 | 23 |
Why?
|
Antibodies | 1 | 2008 | 159 |
Why?
|
Muscular Dystrophies, Limb-Girdle | 1 | 2006 | 3 |
Why?
|
Abstracting and Indexing as Topic | 1 | 2006 | 8 |
Why?
|
Extremities | 1 | 1997 | 32 |
Why?
|
Electrodiagnosis | 1 | 2007 | 17 |
Why?
|
Genes, Dominant | 1 | 1997 | 68 |
Why?
|
Risk Assessment | 2 | 2005 | 324 |
Why?
|
Action Potentials | 1 | 2007 | 77 |
Why?
|
Data Collection | 1 | 2006 | 137 |
Why?
|
Time Factors | 9 | 1984 | 896 |
Why?
|
Arm | 2 | 1997 | 48 |
Why?
|
Clinical Trials as Topic | 9 | 1981 | 251 |
Why?
|
Pain | 2 | 2000 | 191 |
Why?
|
Weight Gain | 4 | 1991 | 30 |
Why?
|
Aged | 6 | 1989 | 988 |
Why?
|
rev Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 3 |
Why?
|
Oxandrolone | 1 | 2001 | 3 |
Why?
|
HIV Long Terminal Repeat | 1 | 2001 | 7 |
Why?
|
Anabolic Agents | 1 | 2001 | 7 |
Why?
|
DNA, Recombinant | 1 | 2001 | 34 |
Why?
|
Virus Assembly | 1 | 2001 | 8 |
Why?
|
Genes, Viral | 1 | 2001 | 37 |
Why?
|
Response Elements | 1 | 2001 | 40 |
Why?
|
Infant | 4 | 1983 | 464 |
Why?
|
Transgenes | 1 | 2001 | 56 |
Why?
|
Follow-Up Studies | 5 | 1985 | 553 |
Why?
|
Viral Envelope Proteins | 1 | 2001 | 26 |
Why?
|
Leprosy | 1 | 2000 | 3 |
Why?
|
Nociceptors | 1 | 2000 | 14 |
Why?
|
Models, Genetic | 1 | 2001 | 90 |
Why?
|
Affect | 1 | 2010 | 55 |
Why?
|
Muscle Fatigue | 1 | 1999 | 10 |
Why?
|
Longitudinal Studies | 1 | 2011 | 195 |
Why?
|
Cloning, Molecular | 1 | 2001 | 183 |
Why?
|
Viral Proteins | 1 | 2001 | 71 |
Why?
|
DNA, Viral | 1 | 2001 | 98 |
Why?
|
Nerve Growth Factors | 1 | 2000 | 43 |
Why?
|
Contracture | 4 | 1983 | 14 |
Why?
|
Cell Division | 1 | 2001 | 273 |
Why?
|
Multiple Sclerosis | 1 | 1999 | 43 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 176 |
Why?
|
Skin | 1 | 2000 | 177 |
Why?
|
Disease Progression | 2 | 1997 | 244 |
Why?
|
Transcription, Genetic | 1 | 2001 | 253 |
Why?
|
Cell Line | 1 | 2001 | 375 |
Why?
|
Random Allocation | 4 | 1987 | 160 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 402 |
Why?
|
Computers | 2 | 1981 | 58 |
Why?
|
Respiratory Function Tests | 3 | 1987 | 72 |
Why?
|
Creatine Kinase | 2 | 1981 | 37 |
Why?
|
Prospective Studies | 3 | 1987 | 545 |
Why?
|
Azathioprine | 1 | 1993 | 13 |
Why?
|
Electromyography | 3 | 1987 | 55 |
Why?
|
Reproducibility of Results | 3 | 1992 | 391 |
Why?
|
Injections, Subcutaneous | 1 | 2010 | 63 |
Why?
|
Drug Combinations | 1 | 2010 | 95 |
Why?
|
Physical Therapy Specialty | 1 | 2009 | 2 |
Why?
|
Language Disorders | 1 | 2009 | 14 |
Why?
|
Nutritional Requirements | 1 | 2009 | 15 |
Why?
|
United States | 2 | 2006 | 604 |
Why?
|
Respiration Disorders | 1 | 2009 | 9 |
Why?
|
Gastrointestinal Diseases | 1 | 2009 | 31 |
Why?
|
Aged, 80 and over | 2 | 2006 | 599 |
Why?
|
Exercise Therapy | 1 | 2009 | 28 |
Why?
|
Bone Diseases | 1 | 2009 | 23 |
Why?
|
Pain Management | 1 | 2009 | 32 |
Why?
|
Early Diagnosis | 1 | 2009 | 23 |
Why?
|
Age of Onset | 1 | 2009 | 64 |
Why?
|
Penicillamine | 1 | 1988 | 14 |
Why?
|
Heart Diseases | 1 | 2009 | 92 |
Why?
|
Placebo Effect | 1 | 2008 | 26 |
Why?
|
Internationality | 1 | 2008 | 28 |
Why?
|
Ambulatory Care | 1 | 2009 | 106 |
Why?
|
Vitamin E | 1 | 1988 | 38 |
Why?
|
Testosterone | 1 | 1989 | 57 |
Why?
|
Muscle Relaxation | 1 | 2007 | 18 |
Why?
|
Motor Activity | 1 | 2009 | 104 |
Why?
|
Placebos | 2 | 1993 | 110 |
Why?
|
Trinucleotide Repeats | 1 | 2007 | 15 |
Why?
|
Evidence-Based Medicine | 1 | 2009 | 125 |
Why?
|
Muscle Weakness | 1 | 2007 | 25 |
Why?
|
Creatinine | 2 | 1981 | 69 |
Why?
|
Iowa | 1 | 2006 | 5 |
Why?
|
Colorado | 1 | 2006 | 11 |
Why?
|
Arizona | 1 | 2006 | 9 |
Why?
|
Dystroglycans | 1 | 2006 | 5 |
Why?
|
Needles | 1 | 2007 | 24 |
Why?
|
Caveolin 1 | 1 | 2006 | 12 |
Why?
|
Body Composition | 1 | 1997 | 44 |
Why?
|
Leg | 1 | 2007 | 75 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 1996 | 14 |
Why?
|
Animals | 2 | 1999 | 1031 |
Why?
|
Organ Size | 1 | 1997 | 118 |
Why?
|
Comorbidity | 1 | 2008 | 190 |
Why?
|
Immunophenotyping | 1 | 2006 | 66 |
Why?
|
Blotting, Southern | 1 | 1996 | 69 |
Why?
|
Calpain | 1 | 2006 | 15 |
Why?
|
Questionnaires | 1 | 2011 | 360 |
Why?
|
Activities of Daily Living | 1 | 2008 | 122 |
Why?
|
Incidence | 1 | 2008 | 336 |
Why?
|
Muscle Proteins | 1 | 2006 | 56 |
Why?
|
Time | 1 | 2005 | 41 |
Why?
|
Predictive Value of Tests | 1 | 2007 | 321 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 427 |
Why?
|
Leucine | 1 | 1984 | 53 |
Why?
|
Prevalence | 1 | 2006 | 281 |
Why?
|
Movement | 1 | 1985 | 69 |
Why?
|
Blotting, Western | 1 | 2006 | 275 |
Why?
|
Body Weight | 2 | 1991 | 178 |
Why?
|
Phenotype | 1 | 1996 | 303 |
Why?
|
Motor Skills | 1 | 1983 | 28 |
Why?
|
Retrospective Studies | 1 | 2009 | 653 |
Why?
|
Respiration | 1 | 1983 | 78 |
Why?
|
New York | 1 | 2006 | 422 |
Why?
|
Membrane Proteins | 1 | 2006 | 233 |
Why?
|
Muscle Tonus | 1 | 2001 | 8 |
Why?
|
Carnitine | 1 | 1981 | 11 |
Why?
|
Quality Control | 1 | 1981 | 54 |
Why?
|
Risk Factors | 1 | 2008 | 555 |
Why?
|
Body Mass Index | 1 | 2001 | 122 |
Why?
|
Muscular Diseases | 1 | 1981 | 36 |
Why?
|
Thiolester Hydrolases | 1 | 2000 | 5 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2000 | 7 |
Why?
|
Statistics, Nonparametric | 1 | 2001 | 141 |
Why?
|
Pain Threshold | 1 | 2000 | 11 |
Why?
|
Physical Stimulation | 1 | 2000 | 28 |
Why?
|
Reflex | 1 | 2000 | 33 |
Why?
|
Drug Therapy, Combination | 2 | 1988 | 189 |
Why?
|
Vasodilation | 1 | 2000 | 30 |
Why?
|
Hot Temperature | 1 | 2000 | 93 |
Why?
|
Keratinocytes | 1 | 2000 | 36 |
Why?
|
Sodium Channels | 1 | 2000 | 32 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2000 | 40 |
Why?
|
In Situ Hybridization | 1 | 2000 | 135 |
Why?
|
Axons | 1 | 2000 | 66 |
Why?
|
Absorptiometry, Photon | 1 | 1998 | 26 |
Why?
|
Models, Biological | 1 | 1994 | 410 |
Why?
|
Age Factors | 1 | 1981 | 480 |
Why?
|
Immunohistochemistry | 1 | 2000 | 355 |
Why?
|
Research Design | 2 | 1987 | 169 |
Why?
|
Biomechanics | 1 | 1994 | 79 |
Why?
|
Body Height | 1 | 1993 | 36 |
Why?
|
Pain Measurement | 1 | 1994 | 98 |
Why?
|
Observer Variation | 1 | 1992 | 103 |
Why?
|
Wheelchairs | 1 | 1989 | 5 |
Why?
|
Locomotion | 1 | 1989 | 24 |
Why?
|
Acne Vulgaris | 1 | 1989 | 10 |
Why?
|
Cardiomyopathies | 1 | 1989 | 43 |
Why?
|
Scoliosis | 1 | 1989 | 20 |
Why?
|
Analysis of Variance | 1 | 1991 | 339 |
Why?
|
Drug Evaluation | 1 | 1987 | 54 |
Why?
|
Mice | 1 | 1999 | 623 |
Why?
|
Cost-Benefit Analysis | 1 | 1987 | 118 |
Why?
|
Enzymes | 1 | 1984 | 22 |
Why?
|
Methods | 1 | 1984 | 133 |
Why?
|
Evaluation Studies as Topic | 1 | 1984 | 178 |
Why?
|
Methylhistidines | 1 | 1981 | 5 |
Why?
|
